RecruitingPhase 3NCT07232134

The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia

Studying Down syndrome

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Intervention: 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine).(drug)
Enrollment: 100 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2032

Study locations (1)

National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198, Moscow, Russia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07232134 on ClinicalTrials.gov

Other trials for Down syndrome

Additional recruiting or active studies for the same condition.

See all trials for Down syndrome →

← Back to all trials